The Curie Institute was originally created as the Institut du Radium in 1909 by Marie Curie, at that time already a Nobel Prize winner in Physics, and later in Chemistry. Marie Curie was one of the pioneers of radiation research and radiotherapy, and, as such, the Curie Institute was one of the first centers to offer this treatment to patients. Now, the primary goal of The Curie Institute is to contribute to research in cancer, with a heavily translational focus. Radiation biology and its applications to cancer is one of the primary research focuses of the institute, with the state of the art Proton therapy center being one of our greatest resources. Over its three sites in the Paris region (in Paris center, Saint-Cloud and Orsay), the Curie Institute employs over 3,500 staff, including researchers and medical professionals.
The first laboratory involved in THERADNET is the ‘Tumor Signaling and progression’ team of Dr Celio Pouponnot and Prof. Alain Eychene, based at the Curie Institute, Orsay, France, in. This lab focuses on research on different aspects of both Medulloblastoma and Melanoma. While the primary focus of this lab is not on Radiotherapy, radiation and its effects on cancer remain a focal point.
The second laboratory involved in THERADNET is the ‘DNA Repair, radiation and innovative cancer therapies’ laboratory of Marie Dutreix. The research conducted in the Dutreix team mainly focuses on all the beneficial properties of FLASH radiotherapy together with the design and evaluation of the DNA damage repair inhibitor and Radiosensitizer AsiDNA.